We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Marketed Pancreatic Insufficiency Drug Gets Complete Response
Marketed Pancreatic Insufficiency Drug Gets Complete Response
September 18, 2009
Digestive Care has received a complete response letter for Pancrecarb as part of the FDA’s requirement that marketed exocrine pancreatic insufficiency drugs obtain approved NDAs.